WeHealth by Servier, Servier Group’s e-health Business unit, and MobioSense, a leading semiconductor biosensor platform developer based in Taiwan and Boston, announced the closing of a partnership agreement to develop and commercialise a digital portable, High Sensitivity Troponin I Test (hs-cTnI) to accelerate and improve the diagnostic for potential myocardial infarction patients.
A press release reports that Mobiosense’s Solution is the first portable myocardial infarction detection device. The solution under development is a point-of-care hs-cTnI device enabling bedside testing in ambulance, urgent care and hospital emergency room, efficiently reducing current six to 12 hours conventional Troponin protocol to just one hour with the new portable hs-cTnI. The MobioSense’s Solution is helping patients and healthcare providers by increasing the quality of patient care and reducing hospital stay.
As part of this partnership devoted to the co-developing and commercialising of the first solution, Mobiosense will receive financial milestones and resources support. David Guez, Director of WeHealth by Servier comments: “We are pleased to work with MobioSense and with the Masschallenge Healthtech in Boston, where the startup was accelerated to co-develop the business model and the product. This solution is really focused on reducing the pain point of the patient journey and will fit very well with our digital portfolio.”
The Mobiosense’s Solution has gained significant traction thanks to MassChallenge, Philips HealthWorks accelerators and Massachusetts General Hospital (MGH) Co. Create programme. In addition to the development and distribution partnership with WeHealth by Servier, MobioSense seeks to provide a convenient and decentralised biomarker testing platform to revolutionize the point of care testing market.
